Monaco Asset Management SAM Boosts Stock Holdings in Teladoc Health, Inc. $TDOC

Monaco Asset Management SAM lifted its stake in Teladoc Health, Inc. (NYSE:TDOC) by 31.3% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 755,000 shares of the health services provider’s stock after buying an additional 180,000 shares during the period. Teladoc Health makes up approximately 0.4% of Monaco Asset Management SAM’s portfolio, making the stock its 17th biggest holding. Monaco Asset Management SAM’s holdings in Teladoc Health were worth $5,836,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Teacher Retirement System of Texas grew its position in Teladoc Health by 5.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 26,592 shares of the health services provider’s stock worth $232,000 after acquiring an additional 1,431 shares during the last quarter. Federated Hermes Inc. boosted its stake in shares of Teladoc Health by 0.5% during the third quarter. Federated Hermes Inc. now owns 307,700 shares of the health services provider’s stock valued at $2,379,000 after purchasing an additional 1,450 shares during the period. State of Wyoming grew its holdings in shares of Teladoc Health by 2.1% in the third quarter. State of Wyoming now owns 79,075 shares of the health services provider’s stock worth $611,000 after purchasing an additional 1,628 shares during the last quarter. Westside Investment Management Inc. increased its stake in shares of Teladoc Health by 28.6% in the third quarter. Westside Investment Management Inc. now owns 11,250 shares of the health services provider’s stock worth $87,000 after buying an additional 2,500 shares during the period. Finally, AE Wealth Management LLC increased its stake in shares of Teladoc Health by 25.6% in the second quarter. AE Wealth Management LLC now owns 14,747 shares of the health services provider’s stock worth $128,000 after buying an additional 3,010 shares during the period. Institutional investors own 76.82% of the company’s stock.

Insider Transactions at Teladoc Health

In related news, insider Fernando M. Rodrigues sold 4,209 shares of the company’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $7.48, for a total value of $31,483.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Charles Divita III sold 17,138 shares of the stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $7.63, for a total value of $130,762.94. Following the completion of the transaction, the chief executive officer owned 201,036 shares of the company’s stock, valued at approximately $1,533,904.68. This trade represents a 7.86% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 33,288 shares of company stock valued at $251,684. Company insiders own 0.58% of the company’s stock.

Teladoc Health Stock Performance

Teladoc Health stock opened at $4.75 on Friday. Teladoc Health, Inc. has a fifty-two week low of $4.40 and a fifty-two week high of $12.69. The stock’s 50 day simple moving average is $6.23 and its two-hundred day simple moving average is $7.27. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.60 and a current ratio of 2.70. The stock has a market cap of $842.10 million, a price-to-earnings ratio of -3.71 and a beta of 2.12.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on TDOC. Citigroup cut their price target on shares of Teladoc Health from $10.00 to $9.00 and set a “neutral” rating on the stock in a report on Friday, January 9th. BMO Capital Markets assumed coverage on Teladoc Health in a research note on Thursday, November 13th. They issued a “market perform” rating and a $8.00 target price on the stock. Zacks Research downgraded Teladoc Health from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Barclays began coverage on Teladoc Health in a report on Tuesday, December 9th. They issued an “equal weight” rating and a $8.50 price objective for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Teladoc Health in a research report on Monday, December 29th. Three analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $9.12.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.